Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The aim of this review is to discuss the potential usefulness of a novel class of biochemical markers, neoepitopes, in the context of the US Food and Drug Administration (FDA) Critical Path Initiative, which emphasizes biomarkers of safety and efficacy as areas of pivotal interest. Examples of protein degradation fragments--neoepitopes--that have proven useful for research on bone and cartilage are collagen type I and collagen type II degradation products, respectively. These markers have utility in the translational approach, as they can be used to estimate safety and efficacy in both preclinical models and clinical settings. Biochemical markers of tissue degradation may provide optimal tools, which in combination with other techniques, prove essential to drug discovery and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 1×
“As a result, CTX-I is being used in a large number of studies (Black et al. 2007, McClung et al. 2006, Black et al. 2006, Ravn et al. 1999a, 2000, 2003, Tanko et al. 2004, Chesnut et al. 2000) as an indicator of bone resorption and as one component in a fracture-risk prediction models.”
MethodTherapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Horrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248
Biological markers in osteoarthritis
Rousseau, J.-C., & Delmas, P. D. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0508 · Cited by 237
Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood
Sørensen, M. G., Henriksen, K., Schaller, S., Henriksen, D. B., Nielsen, F. C., Dziegiel, M. H., & Karsdal, M. A. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0725-9 · Cited by 143 · cited 2×
“In addition, in in vitro resorption experiments the CTX-I release is sensitive to inhibitors of bone resorption and can be used to dynamically monitor resorption inhibition occurring while the culture is ongoing (Sorensen et al. 2007a, b, Henriksen et al. 2004, 2005, Karsdal et al. 2005).”
BackgroundSelf-citationOsteoclasts secrete non-bone derived signals that induce bone formation
Karsdal, M. A., Neutzsky-Wulff, A. V., Dziegiel, M. H., Christiansen, C., & Henriksen, K. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.168 · Cited by 112 · cited 8×
“…with mutations in osteoclasts attenuating acidification of the osteoclastic resorption lacunae, has identified inhibition of bone resorption with positive effects on bone formation (Karsdal et al. 2005, 2007b, 2008e, Henriksen et al. 2004, 2007b, Sorensen et al. 2007c, Schaller et al. 2004, 2005b).”
BackgroundResultInfluentialSelf-citation
Cited by
The good and the bad collagens of fibrosis – Their role in signaling and organ function
Karsdal, M. A., Nielsen, S. H., Leeming, D. J., Langholm, L. L., Nielsen, M. J., Manon-Jensen, T., Siebuhr, A., Gudmann, N. S., Rønnow, S., Sand, J. M., et al. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.014 · Cited by 509
Self-citationApplication of biomarkers in the development of drugs intended for the treatment of osteoarthritis
Kraus, V. B., Burnett, B., Coindreau, J., Cottrell, S., Eyre, D., Gendreau, M., Gardiner, J., Garnero, P., Hardin, J., Henrotin, Y., et al. (2011) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2010.08.019 · Cited by 328
The future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 313
Self-citationKarsdal, M. A., Nielsen, M. J., Sand, J. M., Henriksen, K., Genovese, F., Bay-Jensen, A.-C., Smith, V., Adamkewicz, J. I., Christiansen, C., & Leeming, D. J. (2013) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2012.474 · Cited by 279
Self-citationThe minor collagens in articular cartilage
Luo, Y., Sinkeviciute, D., He, Y., Karsdal, M., Henrotin, Y., Mobasheri, A., Önnerfjord, P., & Bay-Jensen, A. (2017) · Protein & Cell · doi:10.1007/s13238-017-0377-7 · Cited by 261
Self-citation
Metadata
- Authors
- Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., Qvist, P., Bay-Jensen, A. C., Dam, E. B., Madsen, S. H., & Christiansen, C.
- Venue
- Biomarkers
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 14
- Issue
- 3
- Pages
- 181-202
- ISSN
- 1354-750X (ISSN-L)
- 1366-5804
- OpenAlex
- W2132302127
- Cited by
- 135
- References
- 13
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. https://app.cochat.ai/papers/10.1080/13547500902777608
- The paper
- Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., Qvist, P., Bay-Jensen, A. C., Dam, E. B., Madsen, S. H., & Christiansen, C. (2009). Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. https://doi.org/10.1080/13547500902777608
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.